Guggenheim Reiterates Buy Rating on Septerna, Inc. (SEPN)
Guggenheim maintains its buy rating for Septerna, Inc. with a price target of $45, a 34.37% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Septerna, Inc. (SEPN) with a price target of $45 on July 1, 2026.
- Guggenheim's $45 price target implies 34.37% upside from Septerna, Inc.'s ($SEPN) current $33.49 share price.
- Shares of SEPN traded at $33.49 on Wednesday, with a market cap of approximately $1.51 billion.
- Other firms like HC Wainwright & Co. and Truist Securities also maintain buy ratings with targets of $40 and $43, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim has reiterated its buy rating for Septerna, Inc. (NasdaqGM: SEPN) with a price target of $45. This update came on July 1, 2026, as shares of Septerna traded at $33.49 on Wednesday.
Analysts Set New Price Targets
On July 1, 2026, Guggenheim maintained its buy rating on Septerna, Inc. with a price target of $45. HC Wainwright & Co. also reiterated a buy rating with a $40 target, while Truist Securities maintained their buy rating, setting a $43 price target. Raymond James previously maintained a buy rating with a $53 target on June 8, 2026.
Septerna, Inc. Stock Down 13.9%
Shares of Septerna, Inc. (NasdaqGM: SEPN) traded near $33.49 on Wednesday. The company has a market capitalization of approximately $1.51 billion. Septerna has a 52-week low of $10.30 and a high of $37.99. The stock's 50-day moving average is $29.11, and the 200-day moving average is $25.41. It has a current ratio of 4.71 and a quick ratio of 4.63, with a debt-to-equity ratio of 6.10.
$SEPN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Septerna, Inc. reported revenues of $72.26 million, reflecting a substantial growth rate of 120.11%. However, the company posted a negative net margin of -49.88% and a return on equity of -9.26%. The next earnings report is anticipated on May 11, 2026.
Insider Buying and Selling at Septerna, Inc.
On June 29, 2026, Samira Shaikhly, Chief People Officer, sold 2,178 shares at an average price of $35.18 and bought the same amount at $6.81. Additionally, Bernard Coulie and Alan Ezekowitz each acquired 15,000 shares on June 26, 2026.
About Septerna, Inc.
Septerna, Inc. is a biotechnology company based in South San Francisco, California. It specializes in discovering and developing oral small molecule products targeting G protein-coupled receptors (GPCRs) for treating various diseases, including endocrinology and metabolic disorders. The company is led by CEO Dr. Jeffrey T. Finer and has about 130 employees. Septerna has a collaboration with Novo Nordisk for developing therapies for metabolic diseases.
Bottom Line
Guggenheim's reaffirmation of its buy rating and $45 price target for Septerna, Inc. underscores the firm's confidence in the company's prospects. While the stock trades below its 52-week high, analyst support remains strong with multiple buy ratings. Investors should note that analyst ratings are based on past performance and may not reflect current market conditions.
Get Septerna, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SEPN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.